Expectations for September, page-72

I think it is pretty evident that over the past few years that the current management is NOT competent to take this company to the next level.

While the current management may be very astute at carrying out research and developing potentially great drug/drug platforms, they ARE NOT showing any signs of success when it comes to commercialisation of these products.

Our biggest source of revenue remains as R&D TAX INCENTIVES.

Remember that this is a company that now has THREE products out there on the shelves!! And SPL still cannot generate enough revenue to even break even!